De-novo generation of novel phenotypically active molecules for Chagas disease from biological signatures using AI-driven generative chemistry
Pikusa, M.; Rene, O.; Williams, S.; Chen, Y.-L.; Martin, E.; Godinez, W. J.; Rao, S. P. S.; Guiguemde, A. W.; Nigsch, F.
Show abstract
Designing novel molecules with targeted biological activities and optimized physicochemical properties is a challenging endeavor in drug discovery. Recent developments in artificial intelligence have enhanced the early steps of de novo drug design and compound optimization. Herein, we present a generative adversarial network trained to design new chemical matter that satisfies a given biological signature. Our model, called pqsar2cpd, is based on the activity of compounds across multiple assays obtained via pQSAR (profile-quantitative structure-activity relationships). We applied pqsar2cpd to Chagas disease and designed a novel molecule that was experimentally confirmed to inhibit growth of parasites in vitro at low micromolar concentrations. Altogether, this approach bridges chemistry and biology into one single framework for the design of novel molecules with promising biological activity.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Thinking like a structural biologist: A pocket-based 3D molecule generative model fueled by electron density 96%
- Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning 93%
- HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2 93%
Similar papers in this journal
- TrustAffinity: accurate, reliable and scalable out-of-distribution protein-ligand binding affinity prediction using trustworthy deep learning 93%
- Efficient Generation of Protein Pockets with PocketGen 93%
- A deep learning framework for high-throughput mechanism-driven phenotype compound screening 92%
Similar papers in this journal
- AI-Guided Design of Cyclic Peptide Binders Targeting TREM2 Using CycleRFdiffusion and Experimental Validation 91%
- Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3 91%
- Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.